Literature DB >> 8964418

Intraductal papillary-mucinous tumors of the pancreas: clinicopathologic features, outcome, and nomenclature. Members of the Pancreas Clinic, and Pancreatic Surgeons of Mayo Clinic.

E V Loftus1, B A Olivares-Pakzad, K P Batts, M C Adkins, D H Stephens, M G Sarr, E P DiMagno.   

Abstract

BACKGROUND & AIMS: Intraductal papillary-mucinous tumor (IPMT) of the pancreatic ducts is increasingly recognized. This study investigated if clinical, imaging, or, histological features predicated outcome, formulated a treatment algorithm, and clarified relationships among IPMT, mucinous cystic neoplasms of the pancreas (MCN), and chronic pancreatitis.
METHODS: The medical records, radiographs, and pathological specimens of 15 patients with IPMT (dilated main pancreatic duct or branch ducts with mucin overproduction) who were evaluated between October 1983 and January 1994 were reviewed.
RESULTS: One patient had hepatic metastases. Fourteen underwent an operation (6 distal pancreatectomy, 4 total pancreatectomy, and 4 pancreaticoduodenectomy); all had dysplastic intraductal epithelium and chronic pancreatitis, whereas 3 had invasive adenocarcinoma. After a median of 25 months, 10 patients were alive; 3 of 4 with malignant and 2 of 11 with benign IPMT died (P < 0.05). Patients with or without carcinoma had similar clinical and radiographic features. A clinical diagnosis of chronic pancreatitis had been made in 9 patients with benign IMPT and in none with malignant IPMT (P < 0.05).
CONCLUSIONS: IPMT is a dysplastic and likely precancerous lesion that is frequently diagnosed as chronic pancreatitis and is separate from MCN. Because it is not possible to distinguish noninvasive from invasive IPMT preoperatively, complete surgical excision of the dysplastic process is our treatment of choice whenever appropriate.

Entities:  

Mesh:

Year:  1996        PMID: 8964418     DOI: 10.1053/gast.1996.v110.pm8964418

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  71 in total

1.  Intraductal papillary mucinous tumors (IPMT).

Authors:  J Van de Stadt; J Closset; M Gelin
Journal:  Ann Surg       Date:  1999-12       Impact factor: 12.969

Review 2.  Cystic lesions in the pancreas: when to watch, when to resect.

Authors:  J H Balcom IV; C Fernandez-Del Castillo; A L Warshaw
Journal:  Curr Gastroenterol Rep       Date:  2000-04

3.  Diagnostic and Therapeutic Applications of EUS in Pancreatic Disease.

Authors:  Michelle A Anderson
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-10

4.  Case of intraductal papillary mucinous tumor (noninvasive adenocarcinoma) of the pancreas resected 27 years after onset.

Authors:  Y Shimizu; K Yasui; T Morimoto; A Torii; K Yamao; K Ohhashi
Journal:  Int J Pancreatol       Date:  1999-10

Review 5.  Idiopathic recurrent acute pancreatitis.

Authors:  Luis F Lara; Michael J Levy
Journal:  MedGenMed       Date:  2004-11-15

6.  Treatment strategy of intraductal papillary-mucinous tumor of the pancreas.

Authors:  Kenji Yamao
Journal:  J Gastroenterol       Date:  2005-07       Impact factor: 7.527

7.  A gastric fistula with a pancreatic mucinous tumor.

Authors:  Mehmet Ibiş; Seyfettin Köklü; Omer Başar; Ibrahim Ertuğrul; Selçuk Dişibeyaz; Aysel Ulker
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

8.  Surgical treatment of incidentally identified pancreatic masses.

Authors:  Timothy L Fitzgerald; Andrew J Smith; Max Ryan; Mostafa Atri; Frances C Wright; Calvin H L Law; Sherif S Hanna
Journal:  Can J Surg       Date:  2003-12       Impact factor: 2.089

9.  Advances in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasms, and Pancreatitis.

Authors:  Santhi Swaroop Vege; Stephen J Pandol
Journal:  Gastroenterology       Date:  2018-08-02       Impact factor: 22.682

10.  Intraductal papillary and mucinous pancreatic tumour: a new extracolonic tumour in familial adenomatous polyposis.

Authors:  F Maire; P Hammel; B Terris; S Olschwang; D O'Toole; A Sauvanet; L Palazzo; P Ponsot; B Laplane; P Lévy; P Ruszniewski
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.